BR112012032182A2 - anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano. - Google Patents

anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano.

Info

Publication number
BR112012032182A2
BR112012032182A2 BR112012032182A BR112012032182A BR112012032182A2 BR 112012032182 A2 BR112012032182 A2 BR 112012032182A2 BR 112012032182 A BR112012032182 A BR 112012032182A BR 112012032182 A BR112012032182 A BR 112012032182A BR 112012032182 A2 BR112012032182 A2 BR 112012032182A2
Authority
BR
Brazil
Prior art keywords
cmv
antibodies
human
protein
high affinity
Prior art date
Application number
BR112012032182A
Other languages
English (en)
Inventor
Bo Chen
Fen Zhang
Gizette Sperinde
Krista Maureen Mccutcheon
Lawrence M Kauvar
Minha Park
Orit Foord
Stote Ellsworth
William Usinger
Ying-Ping Jiang
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of BR112012032182A2 publication Critical patent/BR112012032182A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano. anticorpos para proteína gb de citomegalovírus (cmv) humano tem sido isolados de células b humanos. a afinidade desses anticorpos são maiores que a melhor já reportada anteriormente. uma vez que a alta afinidade é crítica para a prevenção de transferência de vírus através da placenta, a invenção de anticorpos são úteis como agentes terapêuticos e profiláticos para prevenir ou amenizar os efeitos da infecção de cmv no feto durante a gravidez.
BR112012032182A 2010-06-16 2011-06-16 anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano. BR112012032182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35549910P 2010-06-16 2010-06-16
PCT/US2011/040761 WO2011159938A2 (en) 2010-06-16 2011-06-16 High affinity human antibodies to human cytomegalovirus (cmv) gb protein

Publications (1)

Publication Number Publication Date
BR112012032182A2 true BR112012032182A2 (pt) 2016-10-25

Family

ID=45348879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032182A BR112012032182A2 (pt) 2010-06-16 2011-06-16 anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano.

Country Status (11)

Country Link
US (3) US9017668B2 (pt)
EP (1) EP2582389B1 (pt)
JP (2) JP6055763B2 (pt)
KR (1) KR101900435B1 (pt)
CN (1) CN103221063B (pt)
AU (1) AU2011268277B2 (pt)
BR (1) BR112012032182A2 (pt)
CA (1) CA2839420C (pt)
IL (1) IL223665B (pt)
RU (1) RU2613421C2 (pt)
WO (1) WO2011159938A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
JP5833565B2 (ja) 2009-12-23 2015-12-16 ４−アンティボディ・アクチェンゲゼルシャフト４−Ａｎｔｉｂｏｄｙ Ａｇ ヒトサイトメガロウイルスに対する結合メンバー
WO2011159938A2 (en) * 2010-06-16 2011-12-22 Trellis Bioscience, Inc. High affinity human antibodies to human cytomegalovirus (cmv) gb protein
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN118465272A (zh) * 2019-12-04 2024-08-09 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
JPWO2007094423A1 (ja) 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
KR20080105111A (ko) 2006-02-28 2008-12-03 온코세라피 사이언스 가부시키가이샤 항 ＥｐｈＡ４ 항체의 효과기 기능을 이용한 세포 손상 방법
US7582298B2 (en) * 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
EP2041570A4 (en) 2006-07-12 2010-02-24 Trellis Bioscience Inc CellSpotTM APPLICATIONS
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
CN100575361C (zh) * 2007-04-28 2009-12-30 中国人民解放军第三军医大学野战外科研究所 抗人巨细胞病毒包膜糖蛋白b的人源化单链抗体
WO2009024445A1 (en) * 2007-08-22 2009-02-26 Ribovax Biotechnologies Sa Antibodies against human cytomegalovirus (hcmv)
RU2364627C2 (ru) * 2007-11-06 2009-08-20 Власик Татьяна Николаевна Экспрессионный вектор для синтеза белков в клетках млекопитающих
AU2009221916A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
AU2009223688B2 (en) * 2008-03-10 2014-12-11 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
SG10201706350PA (en) * 2008-07-16 2017-09-28 Inst For Res In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
WO2011159938A2 (en) * 2010-06-16 2011-12-22 Trellis Bioscience, Inc. High affinity human antibodies to human cytomegalovirus (cmv) gb protein

Also Published As

Publication number Publication date
KR20130086036A (ko) 2013-07-30
US10030069B2 (en) 2018-07-24
US20120020980A1 (en) 2012-01-26
JP2017038612A (ja) 2017-02-23
CN103221063A (zh) 2013-07-24
RU2013101769A (ru) 2014-07-27
JP6055763B2 (ja) 2016-12-27
WO2011159938A2 (en) 2011-12-22
AU2011268277A1 (en) 2013-01-31
EP2582389B1 (en) 2018-02-21
US9017668B2 (en) 2015-04-28
RU2613421C2 (ru) 2017-03-16
IL223665B (en) 2020-01-30
CA2839420A1 (en) 2011-12-22
KR101900435B1 (ko) 2018-09-20
US20170204165A1 (en) 2017-07-20
WO2011159938A3 (en) 2012-04-19
EP2582389A2 (en) 2013-04-24
EP2582389A4 (en) 2014-01-08
US9688744B2 (en) 2017-06-27
AU2011268277B2 (en) 2016-10-27
CN103221063B (zh) 2016-08-24
US20150252099A1 (en) 2015-09-10
JP2013531991A (ja) 2013-08-15
CA2839420C (en) 2023-06-13
AU2011268277A2 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
BR112012032182A2 (pt) anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano.
BR112018006995A2 (pt) receptores anti-cd30 de antígeno quimérico
BR112018068354A2 (pt) células efetoras imunológicas do genoma editado
DOP2017000186A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
CR20170019A (es) Agentes inductores de apoptosis para eltratamiento de cáncer y enfermedades inmunes y autoinmunes
CR20120347A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
BR112012018947B8 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112015020885A2 (pt) polipeptídeos de ligação hiperglicosilados
CR20120631A (es) Agentes inductores de apoptosis para el tratamiento del càncer y de enfermedades inmunes y autoinmunes
EP3746048A4 (en) USE OF CIRCULATING MICROPARTICLES TO STRATIFY THE RISK OF SPONTANEOUS PREMATURE BIRTH
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
EA201390663A1 (ru) Универсальный гель против сухости влагалища с прямым и отсроченным эффектом
BR112018008215A2 (pt) artigo absorvente com canais e elementos elásticos de conformação
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112015021341A2 (pt) anticorpos neutralizantes de flavivírus e métodos de uso dos mesmos
BR112014032682A2 (pt) anticorpo monoclonal humano contra a proteína vp1 do vírus jc
UA112420C2 (uk) Інгібітори апоптозу та їх застосування
EA201691330A1 (ru) Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
EA201691328A1 (ru) Бета-шпилечные пептидомиметики в качестве селективных ингибиторов эластазы
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
BR112017013270A2 (pt) ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?.
WO2014172309A3 (en) Therapeutic compositions for neutralizing type i interferons, and methods of use
BR112015025706A2 (pt) forma de dosagem do antagonista do receptor de progesterona
BR112014004954A2 (pt) sistema para colocar um artigo absorvente aderido ao corpo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]